Related Experiment Video
Updated: Jul 7, 2026
12:08
Improving IV Insulin Administration in a Community Hospital
Published on: June 11, 2012
[Types of insulin therapy].
J Sáez de la Fuente1, V Granja Berna, J M Ferrari Piquero
1Servicio de Farmacia, Hospital Universitario Doce de Octubre, Madrid, España. jsaez.hdoc@salud.madrid.org
Revista Clinica Espanola
|February 12, 2008
Summary
Intensive glycemic control is key for managing diabetes mellitus, with new insulin therapies offering improved treatment regimens. Both type 1 and type 2 diabetes require personalized treatment plans for effective long-term management.
Area of Science:
- Endocrinology
- Metabolic Diseases
- Pharmacology
Background:
- Diabetes mellitus is a chronic condition with significant microvascular and macrovascular complications.
- Effective management necessitates continuous therapeutic control.
- Recent advancements include novel insulin types and delivery systems to better replicate physiological insulin secretion.
Purpose of the Study:
- To review current insulin therapy approaches for diabetes mellitus.
- To differentiate between conventional and intensive insulin regimens.
- To emphasize individualized treatment strategies for both type 1 and type 2 diabetes.
Main Methods:
- Literature review of recent advancements in insulin therapy.
- Analysis of conventional versus intensive insulin regimens.
- Discussion of treatment personalization based on patient characteristics.
Main Results:
- Insulin therapy is categorized into conventional and intensive regimens.
- Intensive glycemic control is the preferred treatment for type 1 diabetes mellitus (T1DM).
- Type 2 diabetes management may initiate with conventional regimens, potentially advancing to intensive therapy.
Conclusions:
- Both type 1 and type 2 diabetes mellitus demand individualized treatment plans.
- Treatment complexity varies, with intensive regimens often preferred for optimal glycemic control.
- Personalized prescription is crucial for addressing unique patient needs and characteristics.
Related Concept Videos
01:27Insulin Formulations: Types and Delivery
Insulin preparations are categorized by their duration of action into short-acting and long-acting types. Two strategies are used to modify insulin's absorption and pharmacokinetic profile: slowing the absorption post-subcutaneous injection, or altering human insulin's amino acid sequence or protein structure. These changes retain the insulin's ability to bind to the insulin receptor, but alter its behavior in solution or after injection.
Short-acting insulins are divided into rapid-acting...
Short-acting insulins are divided into rapid-acting...
01:16Insulin: Dosing Regimen and Adverse Effects
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
01:25Insulin: Biosynthesis, Chemistry, and Preparation
The endoplasmic reticulum (ER) of pancreatic β-cells synthesizes preproinsulin, which consists of a signal peptide, A and B chains, and a C-peptide. Preproinsulin is then cleaved and folded into proinsulin, which translocates to the Golgi apparatus for sorting and packaging into secretory granules. In these granules, enzymatic clipping generates insulin and C-peptide.
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment primarily uses...
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment primarily uses...
01:15Diabetes: Management and Pharmacotherapy
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
01:22Diabetes Mellitus: Overview and Type I Subtype
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
01:12Type I Diabetes I: Introduction
Type 1 diabetes mellitus is a chronic metabolic disorder characterized by an absolute deficiency of insulin resulting from the autoimmune destruction of pancreatic β-cells. Although it can occur at any age, it is most commonly diagnosed in childhood, adolescence, or early adulthood. The loss of insulin production impairs cellular glucose uptake, resulting in persistent hyperglycemia and necessitating lifelong insulin therapy.Autoimmune Destruction of β-CellsThe hallmark of type 1 diabetes is an...